Source:http://linkedlifedata.com/resource/pubmed/id/17994314
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2008-1-3
|
pubmed:abstractText |
Oral anticoagulant treatment for secondary prevention after cerebral ischaemia of presumed arterial origin is associated with a higher bleeding rate than cardioembolic stroke. This discrepancy is only partly explained by known bleeding risk factors. Haemostatic genetic variants and AB0 blood group may be involved. We performed a nested casecontrol study in patients with cerebral ischaemia of presumed arterial origin on anticoagulant treatment (International Normalized Ratio between 3.0-4.5). All 34 cases with non-fatal haemorrhage (10 intracranial and 24 extracranial) and 68 control patients on anticoagulant treatment without such a bleeding were selected from the SPIRIT study. AB0 blood group and 11 haemostatic genetic variants were investigated. The Thr312Ala variant of the alpha fibrinogen gene was associated with a decreased bleeding risk (odds ratio (OR) 0.3 for Ala/Ala and Thr/Ala versus Thr/Thr genotype; 95% CI 0.1-0.8). Factor V Leiden was associated with an increased bleeding risk (OR 11.6; 95% CI 1.3-103). The APOE2 allele (OR 0.5; 95% CI 0.2-1.7) and the Tyr204Phe variant in the factor XIII subunit A (OR 2.1; 0.9-5) had nonsignificant relationships with bleeding risk. AB0 blood group and 7 other genetic variants in coagulation factors II and XIII, vitamin K epoxide reductase complex, beta fibrinogen and apolipoprotein E were not related with the risk of haemorrhage. The Ala312Thr variant in the alpha fibrinogen gene is associated with a decreased and factor V Leiden with an increased bleeding risk in patients on anticoagulant treatment after cerebral ischaemia of presumed arterial origin.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ABO Blood-Group System,
http://linkedlifedata.com/resource/pubmed/chemical/Alanine,
http://linkedlifedata.com/resource/pubmed/chemical/Anticoagulants,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen,
http://linkedlifedata.com/resource/pubmed/chemical/Threonine,
http://linkedlifedata.com/resource/pubmed/chemical/fibrinogen Aalpha
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0340-5354
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
254
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1660-5
|
pubmed:dateRevised |
2009-11-3
|
pubmed:meshHeading |
pubmed-meshheading:17994314-ABO Blood-Group System,
pubmed-meshheading:17994314-Administration, Oral,
pubmed-meshheading:17994314-Aged,
pubmed-meshheading:17994314-Alanine,
pubmed-meshheading:17994314-Anticoagulants,
pubmed-meshheading:17994314-Arteries,
pubmed-meshheading:17994314-Blood Proteins,
pubmed-meshheading:17994314-Brain Ischemia,
pubmed-meshheading:17994314-Case-Control Studies,
pubmed-meshheading:17994314-Confidence Intervals,
pubmed-meshheading:17994314-Female,
pubmed-meshheading:17994314-Fibrinogen,
pubmed-meshheading:17994314-Genetic Variation,
pubmed-meshheading:17994314-Hemorrhage,
pubmed-meshheading:17994314-Humans,
pubmed-meshheading:17994314-International Normalized Ratio,
pubmed-meshheading:17994314-Male,
pubmed-meshheading:17994314-Middle Aged,
pubmed-meshheading:17994314-Odds Ratio,
pubmed-meshheading:17994314-Risk Factors,
pubmed-meshheading:17994314-Threonine
|
pubmed:year |
2007
|
pubmed:articleTitle |
Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin.
|
pubmed:affiliation |
Dept. of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|